These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2252660)

  • 1. Non-heparin hemodialysis with oral administration of newly developed antiplatelet agent.
    Teraoka S; Takahashi K; Suzuki T; Naganuma S; Mineshima M; Hoshino T; Era K; Sanaka T; Agishi T; Ota K
    ASAIO Trans; 1990; 36(3):M212-5. PubMed ID: 2252660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-free hemodialysis with an oral anti-platelet agent.
    Teraoka S; Naganuma S; Takahashi K; Ota K
    ASAIO J; 1992; 38(3):M560-3. PubMed ID: 1457921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro.
    Nomoto K; Saeki T; Kogushi M; Kobayashi H; Fujimori T; Yamatsu I
    Jpn J Pharmacol; 1993 Jan; 61(1):7-12. PubMed ID: 8437372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological aspects of a novel antiplatelet drug, E5510].
    Ikeda Y
    Nihon Rinsho; 1992 Feb; 50(2):366-71. PubMed ID: 1613992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical study to assess the effect of heparin in dialyzer rinsing solutions.
    Opatrný K; Bouda M; Kohoutková L; Vít L; Sefrna F
    Int J Artif Organs; 1997 Feb; 20(2):112-8. PubMed ID: 9093891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease.
    Kaneva K; Bansal V; Hoppensteadt D; Cunanan J; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(4):449-52. PubMed ID: 23463188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose heparinization can be used with DEAE-cellulose hemodialysis membranes.
    Ward RA; Schmidt B; Gurland HJ
    ASAIO Trans; 1990; 36(3):M321-4. PubMed ID: 2252689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.
    Lee KB; Kim B; Lee YH; Yoon SJ; Kang WH; Huh W; Kim DJ; Oh HY; Kim YG
    Nephron Clin Pract; 2004; 97(1):c5-10. PubMed ID: 15153761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-free hemodialysis with a polyacrylonitrile membrane.
    Barth RH; Sodden S; Berlyne GM
    ASAIO Trans; 1989; 35(3):597-600. PubMed ID: 2597544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of Nephral ST dialyzers in hemodialyzed patients with increased risk of bleeding].
    Kopeć J; Sułowicz W
    Przegl Lek; 2010; 67(2):91-4. PubMed ID: 20557006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of piracetam in cuprophan hemodialysis.
    Grekas D; Alivanis P; Karamouzis M; Pyrpasopoulos M; Tourkantonis A
    Artif Organs; 1989 Oct; 13(5):422-6. PubMed ID: 2803050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
    Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
    Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid.
    Fujimori T; Harada K; Saeki T; Kogushi M; Akasaka K; Yamagishi Y; Yamatsu I
    Arzneimittelforschung; 1987 Oct; 37(10):1143-8. PubMed ID: 3124862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis without heparin infusion using Cordis Dow 3500 hollow fiber.
    Raja R; Kramer M; Rosenbaum JL; Bolisay C; Krug M
    Proc Clin Dial Transplant Forum; 1980; 10():39-42. PubMed ID: 7346852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
    Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
    Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocompatibility of heparin-grafted hemodialysis membranes: impact on monocyte chemoattractant protein-1 circulating level and oxidative status.
    Morena M; Jaussent I; Chalabi L; Bargnoux AS; Dupuy AM; Badiou S; Rakic C; Thomas M; Canaud B; Cristol JP; Michel F
    Hemodial Int; 2010 Oct; 14(4):403-10. PubMed ID: 20955273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.